REGENXBIO (NASDAQ:RGNX - Get Free Report) had its price target dropped by analysts at HC Wainwright from $36.00 to $34.00 in a report released on Monday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. HC Wainwright's target price suggests a potential upside of 312.62% from the company's previous close. HC Wainwright also issued estimates for REGENXBIO's Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.
Several other brokerages have also issued reports on RGNX. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Royal Bank of Canada restated an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Raymond James initiated coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. The Goldman Sachs Group cut REGENXBIO from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Morgan Stanley lifted their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, REGENXBIO presently has an average rating of "Moderate Buy" and a consensus target price of $33.88.
Check Out Our Latest Research Report on RGNX
REGENXBIO Stock Down 1.4 %
NASDAQ:RGNX traded down $0.12 on Monday, hitting $8.24. The stock had a trading volume of 2,493,911 shares, compared to its average volume of 709,638. The company has a fifty day moving average price of $7.29 and a two-hundred day moving average price of $8.93. REGENXBIO has a 1-year low of $5.62 and a 1-year high of $23.14. The stock has a market cap of $408.25 million, a price-to-earnings ratio of -1.64 and a beta of 1.35.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, analysts anticipate that REGENXBIO will post -4.84 earnings per share for the current year.
Hedge Funds Weigh In On REGENXBIO
A number of institutional investors and hedge funds have recently made changes to their positions in RGNX. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of REGENXBIO in the 3rd quarter valued at approximately $643,000. Intech Investment Management LLC acquired a new stake in REGENXBIO in the third quarter valued at $161,000. Charles Schwab Investment Management Inc. raised its stake in REGENXBIO by 9.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock valued at $4,382,000 after buying an additional 37,055 shares in the last quarter. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,656 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in REGENXBIO by 602.9% during the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after purchasing an additional 17,533 shares during the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
